LudwigBurger Profile Banner
Ludwig Burger Profile
Ludwig Burger

@LudwigBurger

Followers
308
Following
24
Media
2
Statuses
122

Senior Correspondent at Thomson Reuters - views expressed are my own

Joined December 2010
Don't wanna be here? Send us removal request.
@chemicalandi
andrew noel
2 years
The chemical industry’s path toward sustainability was never going to linear. @UmicoreGroup #EVs https://t.co/PILwpou1p9
0
1
1
@LudwigBurger
Ludwig Burger
2 years
It would be a cash call for all the wrong reasons, but some sell-side and buy-side analysts are giving serious thought to that scenario at embattled #Bayer. With @EmmaVictoriaF and Patricia Weiss https://t.co/Typ8xJ9TNz
0
0
0
@LudwigBurger
Ludwig Burger
3 years
New #Bayer CEO Bill Anderson is walking the talk about too much red tape at the German healthcare and agriculture company. But that should only be a step on the way to bigger changes. https://t.co/N9dE98Lpi1
Tweet card summary image
reuters.com
Bayer's new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people...
0
0
1
@Reuters_Health
Reuters Health
3 years
Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters.
Tweet card summary image
reuters.com
Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters.
0
1
0
@LudwigBurger
Ludwig Burger
3 years
A debate to follow when #Wegovy comes to market in Germany this month: Will there be, at some point, any change in drug coverage policies that some say reflects a stigmatisation of obesity? https://t.co/fsbvhZ6aYM
Tweet card summary image
reuters.com
Frustrated after countless failed diet and exercise attempts, 41 year-old Jessica Lenth from Hamburg has started putting money aside for a drug that she sees as a possible door to a life without...
0
0
1
@LudwigBurger
Ludwig Burger
3 years
#NovoNordisk's #Wegovy is coming to self-payer market Germany for a little over €300 per month. Overwhelmed by demand elsewhere, the company is already pleading for restraint with German doctors. https://t.co/NkkiJiDcC5
Tweet card summary image
reuters.com
Novo Nordisk on Friday urged doctors in Germany to limit prescriptions of its popular Wegovy weight-loss drug to patients with medical needs, citing limited supplies as the company prepares to launch...
0
0
2
@LudwigBurger
Ludwig Burger
3 years
German hidden champion Freiberger Compound Materials consumes about 10% of the global #gallium production. It is for now relatively relaxed about Chinese export controls but its clients clearly are not. https://t.co/FvJDpYvxVC
Tweet card summary image
reuters.com
China's planned export controls on gallium have caused frantic stockpiling of speciality semiconductor wafers made from the metal, according to the world's largest gallium buyer.
0
0
1
@LudwigBurger
Ludwig Burger
3 years
Europe's public-health policy makers are largely immune to the hype over new #obesity drugs. Case in point: Germany is developing a disease management programme for obesity but a no-reimbursement rule for weight-loss drugs will not be touched. https://t.co/6IWMht4qxe
Tweet card summary image
reuters.com
Novo Nordisk will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health...
0
0
1
@LudwigBurger
Ludwig Burger
3 years
Sanofi, one of the largest influenza vaccines suppliers, says the industry's current generation of mRNA flu vaccine candidates will not be up to the task. Will we hear Pfizer, BioNTech and Moderna say 'speak for yourself' ? https://t.co/XG22IlnUMY
Tweet card summary image
reuters.com
Sanofi said that trials show the currently available mRNA technology behind the most successful COVID-19 shots will not be effective against influenza and it is already working on a next generation...
0
0
2
@LudwigBurger
Ludwig Burger
3 years
#BlueRock, acquired by #Bayer in 2019, is making early progress on #parkinsons #parkinsonsdisease stem cell therapy development. A crowded field of research teams around the globe is pursuing this complex technology. https://t.co/egVRre9dea
Tweet card summary image
reuters.com
Bayer subsidiary BlueRock has become the first company to report initial success treating Parkinson's disease in humans using an experimental stem cell therapy, the drugmaker said on Wednesday.
0
1
0
@Quasilocal
Steve McCormick
3 years
Seems about right https://t.co/psvX14RhTg
14
103
828
@BallouxFrancois
Prof Francois Balloux
3 years
I personally don't mind if pharmaceutical companies make a lot of money out of those drugs if they delivered. For Big Pharma haters, there's still the consolation that there would be far less money to be made out of diabetes type 2, hypertension, statins and whatnot drugs. 2/
5
7
107
@reuters_csteitz
Christoph Steitz
3 years
"Investors love simple structures, with a clear focus on the core business. This is the case everywhere, not only in Germany," @JoeKaeser tells us. He should know. @Siemens_Energy @Siemens @LudwigBurger
Tweet card summary image
reuters.com
Brenntag, Bayer, Fresenius in the crosshairs of activist investors.
0
1
2
@shellenberger
Michael Shellenberger
3 years
16
86
623
@DanGarrahan
Daniel Garrahan
3 years
The UK's recent disastrous "mini" Budget can trace its origins back to Britain's decision to leave the European Union. The economic costs of Brexit were masked by the pandemic and the Ukraine crisis. But six years after the vote, the Brexit effect is clear
206
2K
4K
@ReutersPR
Reuters Press Team
3 years
Merck KGaA's (@merckgroup) Belen Garijo sits down with @Reuters correspondent @LudwigBurger to discuss key trends in drug development and global microchip production. Register for our #ReutersNEXT Newsmaker this Thursday at 11:00 a.m. GMT. https://t.co/2Tj9ouqRS8
0
1
1